The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma.
复制标题
DOI：
10.1186/s12885-017-3913-1
复制
发表时间：
2017-12-28
期刊：
影响因子：
3.8
通讯作者：
Yamasoba T
中科院分区：
文献类型：
--
作者：
Omura G;Ando M;Ebihara Y;Saito Y;Kobayashi K;Fukuoka O;Akashi K;Yoshida M;Asakage T;Yamasoba T
TP53是人类癌症中最常见的突变基因。以往的研究报道，TP53突变与头颈部鳞状细胞癌（HNSCC）患者的预后不良相关。然而，TP53突变与下咽鳞状细胞癌（HPSCC）之间的关系尚不清楚。目前的研究旨在评估TP53突变状态作为HPSCC患者的预测生物标志物。我们回顾性分析了2008年至2014年期间接受初次手术治疗的57例HPSCC患者的临床图表。通过桑格测序确定TP 53突变状态，并将患者分为野生型、错义突变和截短突变组。此外，p53表达在手术标本中使用免疫组织化学测定。 在39例（68%）患者中发现TP53突变。野生型、错义突变和截短突变组的3年疾病特异性生存率（DSS）分别为94%、61%和43%。TP53突变组的DSS和总生存率显著低于野生型组（分别为P = 0.01和P = 0.007）。多因素分析显示TP53突变和≥4个淋巴结转移是影响HPSCC预后的独立因素。22例p53免疫阳性，其中野生型5例（28%），错义突变17例（71%），截短突变无1例（P = 0.0001）。TP53突变状态与手术治疗的HPSCC患者预后不良相关。具体而言，截短突变，未检测到p53免疫组化预测最差的生存。
TP53 is the most frequently mutated gene in human cancers. Previous studies reported that TP53 mutations correlated with poor prognoses in patients with head and neck squamous cell carcinoma (HNSCC). However, the relationship between TP53 mutations and hypopharyngeal squamous cell carcinoma (HPSCC) is not known. The current study aimed to evaluate TP53 mutation status as a predictive biomarker in patients with HPSCC. We retrospectively reviewed the clinical charts of 57 HPSCC patients treated with initial surgery between 2008 and 2014. TP53 mutation status was determined by Sanger sequencing, and patients were classified into wild-type, missense mutation, and truncating mutation groups. Additionally, p53 expression was determined using immunohistochemistry in surgical specimens. TP53 mutations were identified in 39 (68%) patients. The 3-year disease-specific survival (DSS) rate of wild-type, missense mutation, and truncating mutation group were 94%, 61%, and 43%, respectively. The TP53 mutation group displayed significantly worse DSS and overall survival rates than the wild-type group (P = 0.01 and P = 0.007, respectively). Multivariate analyses revealed that the presence of TP53 mutations and ≥4 metastatic lymph nodes were independent adverse prognostic factors for HPSCC. p53 immunopositivity was detected in 22 patients, including 5 (28%) and 17 (71%) patients in the wild-type and missense mutation groups, whereas none of the patients with truncating mutation exhibited p53 immunopositivity (P = 0.0001). The TP53 mutation status correlated with poor prognosis in surgically treated HPSCC patients. Specifically, truncating mutations which were not detected by p53 immunohistochemistry were predictive of worst survival.
登录
查看更多内容
影响因子：
11.5
作者：
Olivier, M;Langerod, A;Borresen-Dale, AL
通讯作者：
Borresen-Dale, AL
影响因子：
158.5
作者：
Poeta, M. Luana;Manola, Judith;Koch, Wayne M.
通讯作者：
Koch, Wayne M.
DOI：
10.1158/1078-0432.ccr-11-2260
发表时间：
2012-01-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Skinner HD;Sandulache VC;Ow TJ;Meyn RE;Yordy JS;Beadle BM;Fitzgerald AL;Giri U;Ang KK;Myers JN
通讯作者：
Myers JN
影响因子：
4.3
作者：
Efeyan, Alejo;Serrano, Manuel
通讯作者：
Serrano, Manuel
影响因子：
4.7
作者：
Asakage, Takahiro;Yokoyama, Akira;Watanabe, Hiroshi
通讯作者：
Watanabe, Hiroshi